Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Aug 10, 2014; 5(3): 412-424
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.412
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.412
Gene signature | MammaPrint | OncotypeDX | MapQuantDX | Breast cancer ındex | PAM 50 assay |
Starting material | FF or stabilized RNA, FFPE | FFPE | FFPE, FF | FFPE | FFPE |
Analytical platform | Microarray, RT-PCR | qRT-PCR | Microarray, qRT-PCR | qRT-PCR | nCounter |
Number of genes | 70 | 21 | 97/9 | 7 | 50 |
Indications | Stage I/II, 5 cm, ER (+), Node (-)/[1-3 Node (+)] | ER(+), Node (-) | ER (+), G2 | ER (+) | All, Node (-) untreated |
Application | Clinical outcome | Clinical outcome, benefit from chemotherapy | Molecular grading prediction of response to TMX | Clinical outcome, prediction of response to TMX | Subtype definition, risk of relapse without treatment |
FDA approved | Yes | No | No | No | No |
ASCO and NCCN recommendation | No | Yes | No | No | No |
- Citation: Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014; 5(3): 412-424
- URL: https://www.wjgnet.com/2218-4333/full/v5/i3/412.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i3.412